spacer
home > > winter 2020 > a scalable solution
PUBLICATIONS


A Scalable Solution




A key issue for small and medium-sized enterprises (SMEs) in life science is the optimal utilisation of their limited resources for moving their product pipeline through clinical development, and launching and marketing their approved products. This is further heightened as both clinical trials and post-marketing activities continue to grow in complexity and scope due to stringent regulatory pressures, patient involvement, and globalisation. Regardless, companies face overwhelming pressure to get their product to market as quickly as possible.

Clinical trials are typically outsourced end-to-end to full-service CROs. SMEs may select CROs for their niche patient recruitment capabilities in certain geographies and therapeutic areas/indications. As a result, some CROs may not always have the required level of expertise and experience in other aspects of clinical trials, such as data management, statistical design and analysis, medical writing, and regulatory submissions.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the author


Susan Najjar at Covance has over 25 years of industry experience with several years in senior leadership and consulting positions. Susan oversaw global marketing activities for Thermo Fisher Scientific’s informatics division, developing growth strategies and implementing innovative marketing programmes. Prior to Thermo, she was accountable for establishing the Gillette Company’s North American Blades and Razors forecasting and planning, executing software product launches at Sun Microsystems, and consulting senior pharma executive teams at Deloitte & Touche. Susan has an MS in Biochemical Engineering from Tufts University, US, and an MBA from MIT Sloan, US.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Injection vials for vaccines for protection against Covid-19

Düsseldorf, July 02, 2020 The vaccines under development to protect against Covid-19 are, like many other drugs, filled in so-called injection or vials made of type 1 borosilicate glass, also known as vials. The large worldwide demand for vials is met by the Gerresheimer Group's plants in Europe, America and Asia, where they are manufactured to high quality standards for customers in the pharmaceutical industry. The Company has already received initial orders for vials for drugs and vaccines against Covid-19.
More info >>

White Papers

Clinical Trials in Emerging Markets: Goldmines or Landmines?

Pharm-Olam, LLC

Over the past decade, biopharmaceutical companies have increasingly turned to emerging markets as a way to reduce clinical trial costs and timelines. Areas such as Eastern Europe, India, and Latin America—with their ready population of treatment naïve patients—can be an answer to the intense competition for patients seen in developed markets. Many of the countries within these regions may now be considered as “emerged” countries but yet, conducting trials in these regions does require some special attention and expertise. Before deciding to conduct studies in these areas, companies should have a full appreciation for the ethical, medical, regulatory, legal, and operational hurdles that must be surmounted for success. Here we highlight a number of those issues and offer our recommendations for how sponsor companies can deal with them effectively.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement